Table 2.
Concentrations of tamoxifen and metabolites
| Dose | Serum | Tumor tissue | Ratio tissue/serum | ||||
|---|---|---|---|---|---|---|---|
| Median (Q1, Q3) (ng/ml) | P a | Median (Q1, Q3) (ng/g) | P | Median (Q1, Q3) | P | ||
| Tamoxifen | 1 | 6.3 (4.4, 9.3) | <0.0001 | 56.1 (38.6, 101.1) | <0.0001 | 9.4 (5.7, 14.5) | 0.35 |
| 5 | 25.7 (19.1, 37) | 216.2 (115.6, 401) | 9.7 (5.5, 17) | ||||
| 20 | 82.1 (69.7, 106.9) | 631.2 (249.4, 1077.2) | 7.1 (3.5, 12) | ||||
| 4OHtam | 1 | 0.3 (0.3, 0.4) | <0.0001 | 4.5 (2.8, 7.9) | <0.0001 | 18.1 (7.7, 28.5) | 0.36 |
| 5 | 1.1 (0.9, 1.4) | 11.1 (5.5, 32.2) | 15.4 (5.7, 30.6) | ||||
| 20 | 3.9 (3, 5.3) | 38.5 (24.6, 81.1) | 10.1 (6.5, 13.6) | ||||
| 4OHNDtam | 1 | 2.6 (1.8, 3.1) | <0.0001 | 31.3 (17.7, 52) | <0.0001 | 11.9 (6.8, 23.9) | 0.63 |
| 5 | 9 (6.7, 12.3) | 80.3 (27, 201.1) | 10.9 (3.7, 15.4) | ||||
| 20 | 37.5 (25.5, 43.9) | 339.6 (157.7, 507.8) | 9.7 (6.1, 27.4) | ||||
| NDtam | 1 | 12.2 (9.1, 16.7) | <0.0001 | 68.6 (37.9, 107.1) | <0.0001 | 6.4 (3, 8.5) | 0.59 |
| 5 | 49.3 (41.2, 68.7) | 226.8 (56.1, 457.4) | 6.4 (1, 11) | ||||
| 20 | 167.6 (147.1, 223.9) | 617.4 (348.1, 1615.9) | 4.3 (2.1, 8.4) | ||||
| NDDtam | 1 | 1.2 (1, 1.9) | <0.0001 | 7.6 (3.2, 11.7) | <0.0001 | 5.7 (3.2, 8.2) | 0.61 |
| 5 | 5.7 (4.4, 8.6) | 21 (7.5, 41.1) | 4.5 (1.4, 8.3) | ||||
| 20 | 24.3 (17.9, 32.2) | 80.9 (28.1, 193.2) | 4.5 (1.7, 8.2) | ||||
| TamNox | 1 | 1 (1, 1.5) | <0.0001 | 1.2 (1, 1.7) | 0.0002 | 1.1 (1, 1.6) | <0.0001 |
| 5 | 5 (3.1, 7.9) | 2.1 (1.2, 4.9) | 0.5 (0.2, 1.3) | ||||
| 20 | 19.8 (11.2, 37.8) | 2.5 (1.6, 6.7) | 0.2 (0.1, 0.2) | ||||
aNon-parametric Wilcoxon test was used to evaluate differences between treatment groups receiving 1, 5 or 20 mg tamoxifen